JP2018534304A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018534304A5 JP2018534304A5 JP2018524713A JP2018524713A JP2018534304A5 JP 2018534304 A5 JP2018534304 A5 JP 2018534304A5 JP 2018524713 A JP2018524713 A JP 2018524713A JP 2018524713 A JP2018524713 A JP 2018524713A JP 2018534304 A5 JP2018534304 A5 JP 2018534304A5
- Authority
- JP
- Japan
- Prior art keywords
- adjuvant
- composition
- poly
- lipid
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021128886A JP2021181462A (ja) | 2015-11-18 | 2021-08-05 | ポリｉ：ｃポリヌクレオチドアジュバント及び脂質系アジュバントを含むアジュバント系及び水を含まないワクチン組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562256875P | 2015-11-18 | 2015-11-18 | |
| US62/256,875 | 2015-11-18 | ||
| PCT/CA2016/051324 WO2017083963A1 (en) | 2015-11-18 | 2016-11-15 | Adjuvanting systems and water-free vaccine compositions comprising a polyi:c polynucleotide adjuvant and a lipid-based adjuvant |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021128886A Division JP2021181462A (ja) | 2015-11-18 | 2021-08-05 | ポリｉ：ｃポリヌクレオチドアジュバント及び脂質系アジュバントを含むアジュバント系及び水を含まないワクチン組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018534304A JP2018534304A (ja) | 2018-11-22 |
| JP2018534304A5 true JP2018534304A5 (enExample) | 2019-10-31 |
| JP6989134B2 JP6989134B2 (ja) | 2022-01-05 |
Family
ID=58717143
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018524713A Expired - Fee Related JP6989134B2 (ja) | 2015-11-18 | 2016-11-15 | ポリｉ：ｃポリヌクレオチドアジュバント及び脂質系アジュバントを含むアジュバント系及び水を含まないワクチン組成物 |
| JP2021128886A Pending JP2021181462A (ja) | 2015-11-18 | 2021-08-05 | ポリｉ：ｃポリヌクレオチドアジュバント及び脂質系アジュバントを含むアジュバント系及び水を含まないワクチン組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021128886A Pending JP2021181462A (ja) | 2015-11-18 | 2021-08-05 | ポリｉ：ｃポリヌクレオチドアジュバント及び脂質系アジュバントを含むアジュバント系及び水を含まないワクチン組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11160861B2 (enExample) |
| EP (1) | EP3377099A4 (enExample) |
| JP (2) | JP6989134B2 (enExample) |
| CN (1) | CN108430505A (enExample) |
| AU (1) | AU2016355926A1 (enExample) |
| CA (1) | CA3005127C (enExample) |
| WO (1) | WO2017083963A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016109880A1 (en) | 2015-01-06 | 2016-07-14 | Immunovaccine Technologies Inc. | Lipid a mimics, methods of preparation, and uses thereof |
| CN108430505A (zh) * | 2015-11-18 | 2018-08-21 | 免疫疫苗技术有限公司 | 包括聚肌胞苷酸多核苷酸佐剂和基于脂质的佐剂的辅助系统以及无水疫苗组合物 |
| WO2018151816A1 (en) * | 2017-02-16 | 2018-08-23 | Modernatx, Inc. | High potency immunogenic compositions |
| WO2018187515A1 (en) | 2017-04-04 | 2018-10-11 | Avidea Technologies, Inc. | Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response |
| CA3069019A1 (en) * | 2017-07-10 | 2019-01-17 | Immunovaccine Technologies Inc. | Pharmaceutical compositions, methods for preparation using lipid vesicle particles of defined size, and uses thereof |
| KR102098097B1 (ko) * | 2017-08-16 | 2020-05-26 | 주식회사 차백신연구소 | 리포펩티드가 삽입된 리포좀을 유효성분으로 포함하는 백신 아쥬반트 및 이의 용도 |
| WO2019061297A1 (zh) * | 2017-09-29 | 2019-04-04 | 苏州工业园区唯可达生物科技有限公司 | 一种cd4辅助性t细胞表位融合肽及其疫苗 |
| CN111565706A (zh) * | 2017-11-09 | 2020-08-21 | 免疫疫苗技术公司 | 药物组合物、包括脂质囊泡颗粒尺寸设定的制备方法及其用途 |
| MA53543A (fr) | 2018-09-04 | 2021-07-14 | Treos Bio Ltd | Vaccins peptidiques |
| KR102292147B1 (ko) * | 2020-11-18 | 2021-08-23 | 주식회사 차백신연구소 | 경구용 항바이러스제 및 리포펩타이드와 폴리(i:c) 아쥬반트를 포함한 치료백신을 유효성분으로 포함하는 만성 b형 간염의 예방 또는 치료용 약제학적 조성물, 약제학적 병용제제, 병용제 키트 |
| BR112023016402A2 (pt) * | 2021-02-16 | 2023-11-21 | Us Health | Nanopartículas de automontagem baseadas em peptídeos anfifílicos |
| JP2024517181A (ja) | 2021-04-28 | 2024-04-19 | ウエヌイグレックオ・ファーマ | 組合せ治療としてｆｘｒアゴニストを使用するｔｌｒ３アゴニストの効果の強い増強 |
| CN118660708A (zh) | 2022-01-25 | 2024-09-17 | 公益财团法人川崎市产业振兴财团 | 用于经皮给药的含有rna的组合物和该组合物的给药方法 |
| WO2024092352A1 (en) * | 2022-11-04 | 2024-05-10 | Immunovaccine Technologies Inc. | Compositions that recruit and activate antigen presenting cells |
| AU2023390365A1 (en) * | 2022-12-08 | 2025-07-03 | Thomas Jefferson University | Immune adjuvants for polysaccharide vaccines |
| WO2024186646A1 (en) * | 2023-03-03 | 2024-09-12 | BioVaxys Inc. | Methods of making lipid adjuvanted compositions |
| WO2024186623A1 (en) * | 2023-03-03 | 2024-09-12 | BioVaxys Inc. | Methods of making dried pharmaceutical compositions |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3906092A (en) | 1971-11-26 | 1975-09-16 | Merck & Co Inc | Stimulation of antibody response |
| IL105554A (en) | 1992-05-05 | 1999-08-17 | Univ Leiden | Peptides of human papillomavirus for use in preparations elicit a human T cell response |
| KR100645448B1 (ko) | 1996-11-20 | 2006-11-13 | 예일 유니버시티 | 세포 아폽토시스를 저해하는 설바이빈 단백질 및 이를 조절하는 방법 |
| CA2203843C (en) | 1997-04-28 | 2013-07-23 | Her Majesty The Queen, In Right Of Canada, As Represented By The Ministe R Of National Defence | Liposome-encapsulated poly iclc |
| WO2002038175A1 (en) | 2000-11-07 | 2002-05-16 | Immunovaccine Technologies Inc. | Vaccines with enhanced immune response and methods for their preparation |
| CA2431500C (en) | 2000-12-08 | 2016-06-07 | Sjoerd Hendrikus Van Der Burg | Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses |
| US7892559B2 (en) | 2002-01-30 | 2011-02-22 | Survac Aps | Survivin-derived peptides and use thereof |
| CA2593714C (en) | 2005-02-04 | 2013-09-10 | Survac Aps | Survivin peptide vaccine |
| JP5227592B2 (ja) | 2005-02-07 | 2013-07-03 | リポテック プロプライエタリー リミテッド | アジュバント物質 |
| US20100129385A1 (en) | 2005-02-08 | 2010-05-27 | Jackson David C | Immunogenic molecules |
| DE602006021408D1 (de) | 2005-04-27 | 2011-06-01 | Univ Leiden Medical Ct | Behandlung von hpv-induzierter intraepithelialer anogenitaler neoplasien |
| CA2523032A1 (en) | 2005-10-07 | 2007-04-07 | Immunovaccine Technologies Inc. | Vaccines for cancer therapy |
| AU2008269721B2 (en) | 2007-05-31 | 2013-01-10 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Intradermal HPV peptide vaccination |
| EP2468763B1 (en) | 2007-05-31 | 2014-06-18 | Academisch Ziekenhuis Leiden h.o.d.n. LUMC | HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines |
| ES2588705T3 (es) | 2007-09-27 | 2016-11-04 | Immunovaccine Technologies Inc. | Uso de liposomas en un vehículo que comprende una fase hidrófoba continua para la entrega de polinucleótidos in vivo |
| BRPI0817484B1 (pt) * | 2007-10-03 | 2021-08-17 | Immunovaccine Technologies Inc | Composição de vacina sem água, processo de produção e o uso dos mesmos |
| KR100900837B1 (ko) * | 2007-12-07 | 2009-06-04 | (주)두비엘 | 리포펩타이드와 폴리(ｉ:ｃ)를 아쥬반트로 포함하는 강력한백신 조성물 |
| WO2009118356A2 (en) | 2008-03-25 | 2009-10-01 | Formac Pharmaceuticals N.V. | Preparation method for solid disupersions |
| CA2723918C (en) | 2008-06-05 | 2018-01-09 | Immunovaccine Technologies Inc. | Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance |
| WO2010123365A1 (en) | 2009-04-24 | 2010-10-28 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Increasing the immunogenicity of epithelial cells infected with human papilloma virus (hpv) |
| GB201019240D0 (en) | 2010-11-15 | 2010-12-29 | Vib Vzw | Respiratory syncytical virus vaccine |
| IN2014CN02581A (enExample) | 2011-10-06 | 2015-08-07 | Immunovaccine Technologies Inc | |
| CA2908042C (en) * | 2013-03-27 | 2023-01-31 | Immunovaccine Technologies Inc. | Method for improving the efficacy of a survivin vaccine in the treatment of cancer |
| KR101501583B1 (ko) * | 2013-03-29 | 2015-03-12 | 주식회사 차백신연구소 | 리포펩티드 및 폴리(ｉ:ｃ)를 포함하는 아쥬반트 및 이를 이용한 개선된 제형의 백신 조성물 |
| CN108430505A (zh) * | 2015-11-18 | 2018-08-21 | 免疫疫苗技术有限公司 | 包括聚肌胞苷酸多核苷酸佐剂和基于脂质的佐剂的辅助系统以及无水疫苗组合物 |
-
2016
- 2016-11-15 CN CN201680078577.1A patent/CN108430505A/zh active Pending
- 2016-11-15 AU AU2016355926A patent/AU2016355926A1/en not_active Abandoned
- 2016-11-15 JP JP2018524713A patent/JP6989134B2/ja not_active Expired - Fee Related
- 2016-11-15 WO PCT/CA2016/051324 patent/WO2017083963A1/en not_active Ceased
- 2016-11-15 EP EP16865342.6A patent/EP3377099A4/en not_active Withdrawn
- 2016-11-15 CA CA3005127A patent/CA3005127C/en active Active
- 2016-11-15 US US15/777,120 patent/US11160861B2/en not_active Expired - Fee Related
-
2021
- 2021-08-05 JP JP2021128886A patent/JP2021181462A/ja active Pending
- 2021-09-21 US US17/480,304 patent/US20220001010A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018534304A5 (enExample) | ||
| Diaz-Arévalo et al. | Nanoparticle-based vaccines: opportunities and limitations | |
| Tan et al. | Outer membrane vesicles: current status and future direction of these novel vaccine adjuvants | |
| US11077184B2 (en) | Liposome compositions comprising PAM2Cys or PAM3Cys adjuvant and methods for inducing a humoral immune response | |
| Wang et al. | Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies | |
| Woodrow et al. | Mucosal vaccine design and delivery | |
| Xu et al. | Intranasal DNA vaccine for protection against respiratory infectious diseases: the delivery perspectives | |
| Huang et al. | Research progress on emulsion vaccine adjuvants | |
| Kaurav et al. | Combined adjuvant-delivery system for new generation vaccine antigens: alliance has its own advantage | |
| JP2014528955A5 (enExample) | ||
| Liu et al. | A novel liposome adjuvant DPC mediates Mycobacterium tuberculosis subunit vaccine well to induce cell-mediated immunity and high protective efficacy in mice | |
| Korsholm et al. | Cationic liposomal vaccine adjuvants in animal challenge models: overview and current clinical status | |
| JP7409594B2 (ja) | 医薬組成物、規定のサイズの脂質ベシクル粒子を使用する調製物のための方法、及びそれらの使用 | |
| Carneiro et al. | Protective effect of antigen delivery using monoolein-based liposomes in experimental hematogenously disseminated candidiasis | |
| Xiang et al. | Promising particle-based vaccines in cancer therapy | |
| Soni et al. | The sixth revolution in pediatric vaccinology: immunoengineering and delivery systems | |
| US20200054571A1 (en) | Formulation for protection through controlled release of microparticles containing recombinant outer membrane vesicles | |
| Bo et al. | Materials‐based vaccines for infectious diseases | |
| Temchura et al. | Immunogenicity of Recombinant Lipid-Based Nanoparticle Vaccines: Danger Signal vs. Helping Hand | |
| Gandhapudi et al. | Recombinant Protein Vaccines Formulated with Enantio-Specific Cationic Lipid R-DOTAP Induce Protective Cellular and Antibody-Mediated Immune Responses in Mice. Viruses. 2023; 15 (2): 432 | |
| Barik et al. | Nanotechnology-Based Vaccination for TB | |
| Noureddine et al. | Nanoparticle Vaccines for Immunotherapy: From Design to Clinical Trials | |
| Caetano et al. | Chitosan-alginate microparticulate delivery system for an alternative route of administration of BCG vaccine | |
| Balar et al. | Antigen Selection and Design | |
| Becker | Vaccine technologies & the rationale for new nanoparticle formulations |